Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves CSL Behring’s single-chain Afstyla for hemophilia A
Afstyla, which is anticipated to be available in the US early this US summer, is indicated for routine prophylaxis to avoid or reduce the frequency of bleeding episodes;
Afstyla, which is anticipated to be available in the US early this US summer, is indicated for routine prophylaxis to avoid or reduce the frequency of bleeding episodes;
Gazyva/Gazyvaro is an engineered monoclonal antibody designed to attach to CD20, a protein found on several B cells, but not on stem cells or plasma cells. It is
About 500 patients will be enrolled in the randomized, double-blind, placebo-controlled phase 3 study, dubbed Cascade, which will assess 33A in combination with azacitidine (Vidaza) or decitabine (Dacogen)
The 15-member panel of the Endocrinologic and Metabolic Drugs Advisory Committee voted 12 to 2 (1 panelist did not vote due to travel) to approve the combination. Two
ALKS 4230, which was formerly referred to as RDB 1450, a novel selective effector cell activator protein designed to preferentially bind and signal through the intermediate affinity interleukin-2
A total 115 patients were enrolled in the placebo-controlled, randomized, double-blind trial, which evaluated the efficacy and safety of three separate, twice-daily, dosing regimens of Prurisol — 50
Invokamet is a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet. The drug has now been approved as a first-line treatment for adults with type
It is the first application filed in the US by Samsung Bioepis as part of its alliance with Merck to provide biosimilar alternatives to existing biologic medicines. Samsung
A new research team of scientists established by the companies had submitted the most promising solution approaches in a crowdsourcing competition. The interdisciplinary team, which will be led
Darzalex, which is being developed jointly by Genmab and Janssen Biotech, is a human IgG1k monoclonal antibody that binds to CD38, a protein expressed on the surface of